Finerenone in Heart Failure: The Complete Picture (2024-2026)

First, Clear Up the Torsemide Comparison

The Pivotal Trial: FINEARTS-HF (NEJM, 2024)

• Population: 6,001 patients with HF and EF ≥40% (HFmrEF + HFpEF)
• Dose: Finerenone up to 20 mg or 40 mg once daily (vs. placebo)
• Median follow-up: 32 months
• Primary outcome: Total worsening HF events + CV death

• 16% relative risk reduction in primary composite (rate ratio 0.84; 95% CI 0.74-0.95; p=0.007)
• Worsening HF hospitalizations: rate ratio 0.82 (p=0.006)
• CV mortality: HR 0.93 (non-significant - no mortality benefit in HFpEF/HFmrEF)
• Hyperkalemia: increased (9.7% vs 4.2%), but serious hyperkalemia (K+ >6.0 mmol/L) was low

Is Finerenone Better Than Spironolactone?

• Steroidal MRAs (spironolactone, eplerenone) reduce CV death + HF hospitalization primarily in HFrEF (HR 0.66)
• Finerenone (non-steroidal MRA) reduces CV death + HF hospitalization in HFmrEF/HFpEF (HR 0.87) - TOPCAT (spironolactone in HFpEF) was essentially neutral
• The p for interaction = 0.0012 - this is a real, statistically meaningful difference by ejection fraction class

• HF exacerbation: 55.2% vs 72.9% (HR 0.63, p<0.001) - finerenone wins
• All-cause mortality: 4.1% vs 11.8% (HR 0.38, p<0.001) - finerenone wins
• Hypokalemia: lower with finerenone (8.4% vs 15.1%)

Why Is Finerenone Mechanistically Better?

1. Tissue distribution: Finerenone distributes equally to the heart AND kidneys, whereas eplerenone concentrates 3x more in kidney, and spironolactone is even more kidney-predominant. For cardiac fibrosis blockade, equal distribution matters.
2. Receptor selectivity: Finerenone, like eplerenone, has low affinity for androgen and progesterone receptors. Spironolactone binds both avidly, causing gynecomastia, breast tenderness, and sexual dysfunction - often a reason patients stop the drug.
3. Higher binding affinity to MR: Finerenone has ~10x higher MR-binding potency than spironolactone, with a distinct conformational change in the receptor that may produce a different gene transcription profile - more anti-fibrotic, less anti-natriuretic.
4. Short half-life (2-3 hours): This limits sustained hyperkalemia peaks, though clinically hyperkalemia still occurs.
5. No diuretic effect: Unlike spironolactone, finerenone does not cause meaningful natriuresis. This is actually an advantage in the HFpEF population who are not fluid overloaded at baseline, as it avoids electrolyte imbalances and hemodynamic effects.

When to Use Finerenone - Practical Guide

Use Finerenone First (over spironolactone) When:

• HFmrEF or HFpEF (EF ≥40%) - it has positive trial data; spironolactone (TOPCAT) does not
• CKD + T2DM + albuminuria - FIDELIO/FIGARO showed both renal and CV protection; guideline-supported
• Patient with gynecomastia or sexual side effects on spironolactone - no androgen receptor activity
• Patient who develops hyperkalemia on spironolactone - somewhat lower risk, though still needs monitoring
• Concurrent SGLT2 inhibitor use is NOT a reason to avoid it - FINEARTS-HF showed additive benefit regardless of SGLT2i use (Vaduganathan et al., Circulation 2025)

Stick with Spironolactone/Eplerenone When:

• HFrEF (EF <40%) - proven mortality benefit in RALES and EMPHASIS-HF; no finerenone trial in this group
• Cost is a barrier - spironolactone is cheap and generic; finerenone is expensive
• No CKD/DM phenotype driving the prescription
• eGFR <25 mL/min/1.73 m² or K+ >4.8-5.0 mmol/L - both drugs are contraindicated, but this is not a reason to choose one over the other

Dosing (Finerenone):

• Start 10 mg/day if eGFR 25-60 mL/min/1.73 m²
• Start 20 mg/day if eGFR >60 mL/min/1.73 m²
• Target 40 mg/day in HF trial
• Check potassium at 4 weeks; hold if K+ >5.0 mmol/L

Guideline Status (2025-2026)

• FDA (July 2025): Approved for HF with EF ≥40% - first MRA approved for this indication
• Japanese JCS/JHFS 2025 guidelines: Finerenone elevated to Class IIa for HFpEF; spironolactone/eplerenone remain Class IIb
• ESC 2023: Class IIb for HFmrEF; no recommendation for HFpEF - this predates FINEARTS-HF and is expected to be updated
• AHA/ACC: Update pending post-FINEARTS-HF

Bottom Line